Redhill Biophrma ADR (RDHL)

$1.22 -0.15 (-10.95%)
Market Cap 4.68M
Revenue (ttm) 8.04M
Net Income (ttm) -8.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -102.86%
Debt to Equity Ratio 0.00
Volume 291,808
Avg Vol 1,164,186
Day's Range N/A - N/A
Shares Out 4.54M
Stochastic %K 90%
Beta 4.87
Analysts Strong Buy
Price Target $40.00

Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear ra...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 972 3 541 3131
Fax: 972 3 541 3144
Address:
21 Ha’arba’a Street, Tel Aviv, Israel
Michl2000
Michl2000 Jan. 7 at 8:34 PM
$RDHL back to 1.00€ and below 😏
0 · Reply
StockScanners
StockScanners Jan. 7 at 5:40 AM
$RDHL reached 1.41
0 · Reply
BUKUDATBULL
BUKUDATBULL Jan. 6 at 9:42 PM
Waiting on my $GPUS Like 🫣 🙄MOVE YO AZZ ALREADY!$$$ jk $RDHL $OCG $SAFX
0 · Reply
SchumpeterSchlaumeier
SchumpeterSchlaumeier Jan. 6 at 7:32 PM
$RDHL squeeze блядь ! I'm with RDHL since 2019 and still believe in this dump🤜🤜🤜
0 · Reply
pln63
pln63 Jan. 6 at 6:48 PM
$RDHL fighting hard!
0 · Reply
DonZulu
DonZulu Jan. 6 at 3:14 PM
$RDHL flagging up
0 · Reply
pln63
pln63 Jan. 6 at 2:55 PM
$RDHL and another thing…Because it uses an established drug (ondansetron) in a new extended-release format, they are using the accelerated 505(b)(2) regulatory pathway, which significantly shortens the time to potential market entry😃
0 · Reply
pln63
pln63 Jan. 6 at 2:33 PM
$RDHL yesterday’s announcement was huge.Their GLP-1 Companion (RHB-102) gives access to a massive market for those needing nausea management. The accompanying nausea is no joke. Multi billion dollar industry potential. Nondilutive cash infuse with the recent $10.5 million legal battle win. I like it 
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 6 at 2:25 PM
$RDHL RSI: 63.83, MACD: -0.0158 Vol: 0.08, MA20: 1.17, MA50: 1.19 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
StockScanners
StockScanners Jan. 6 at 6:43 AM
$RDHL keep watch if this holds above 1.25
0 · Reply
Latest News on RDHL
What's Going On With Redhill Biopharma Stock On Tuesday?

Jan 6, 2026, 10:26 AM EST - 1 day ago

What's Going On With Redhill Biopharma Stock On Tuesday?

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

Jan 5, 2026, 7:00 AM EST - 2 days ago

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells

Dec 15, 2025, 7:00 AM EST - 23 days ago

RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells

RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement

Dec 1, 2025, 7:00 AM EST - 5 weeks ago

RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement

RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

Nov 4, 2025, 9:30 AM EST - 2 months ago

RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

RedHill Biopharma Receives Nasdaq Staff Determination Notification

Oct 22, 2025, 4:50 PM EDT - 2 months ago

RedHill Biopharma Receives Nasdaq Staff Determination Notification

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

Oct 20, 2025, 9:05 AM EDT - 2 months ago

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

CPIX

RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®

Oct 6, 2025, 8:00 AM EDT - 3 months ago

RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®

RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo

Sep 29, 2025, 7:00 AM EDT - 3 months ago

RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo

RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights

Sep 5, 2025, 7:00 AM EDT - 4 months ago

RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights

RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win

Aug 20, 2025, 9:00 AM EDT - 5 months ago

RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win

RedHill Received Talicia® Licensing Payments Totaling $1.1 Million

Aug 18, 2025, 9:00 AM EDT - 5 months ago

RedHill Received Talicia® Licensing Payments Totaling $1.1 Million

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

Jul 21, 2025, 9:00 AM EDT - 6 months ago

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

Jul 1, 2025, 12:00 PM EDT - 6 months ago

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

May 13, 2025, 7:00 AM EDT - 8 months ago

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

May 2, 2025, 7:00 AM EDT - 8 months ago

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

Apr 28, 2025, 7:03 AM EDT - 9 months ago

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

Apr 17, 2025, 4:01 PM EDT - 9 months ago

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

Apr 16, 2025, 7:00 AM EDT - 9 months ago

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

Apr 10, 2025, 7:48 AM EDT - 9 months ago

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

Mar 18, 2025, 7:00 AM EDT - 10 months ago

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

Mar 12, 2025, 7:00 AM EDT - 10 months ago

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

Feb 27, 2025, 7:00 AM EST - 11 months ago

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

Feb 25, 2025, 7:00 AM EST - 11 months ago

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

Feb 4, 2025, 7:00 AM EST - 1 year ago

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Jan 21, 2025, 7:00 AM EST - 1 year ago

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

Dec 10, 2024, 7:00 AM EST - 1 year ago

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

Dec 2, 2024, 7:00 AM EST - 1 year ago

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

Oct 28, 2024, 7:00 AM EDT - 1 year ago

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

Oct 22, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

Oct 14, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

Oct 1, 2024, 7:00 AM EDT - 1 year ago

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

Sep 30, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

Sep 9, 2024, 7:00 AM EDT - 1 year ago

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 5, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

Sep 3, 2024, 7:00 AM EDT - 1 year ago

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

RedHill Biopharma Announces First Half 2024 Business Highlights

Aug 29, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Announces First Half 2024 Business Highlights

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Aug 26, 2024, 7:00 AM EDT - 1 year ago

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Talicia® Launched in the United Arab Emirates

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Talicia® Launched in the United Arab Emirates

Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes

Aug 19, 2024, 8:56 AM EDT - 1 year ago

Israel-Based RedHill's Investigational COVID-19 Treatment Shows Encouraging Action In Obesity And Diabetes

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

Aug 19, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

Aug 16, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

Aug 1, 2024, 7:00 AM EDT - 1 year ago

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

Jul 22, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

RedHill Biopharma Terminates License Agreement for Aemcolo®

Jul 9, 2024, 8:00 AM EDT - 1 year ago

RedHill Biopharma Terminates License Agreement for Aemcolo®

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

Jun 3, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

May 6, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

Apr 24, 2024, 7:00 AM EDT - 1 year ago

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

Apr 8, 2024, 9:23 AM EDT - 1 year ago

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

Apr 2, 2024, 7:00 AM EDT - 1 year ago

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

Michl2000
Michl2000 Jan. 7 at 8:34 PM
$RDHL back to 1.00€ and below 😏
0 · Reply
StockScanners
StockScanners Jan. 7 at 5:40 AM
$RDHL reached 1.41
0 · Reply
BUKUDATBULL
BUKUDATBULL Jan. 6 at 9:42 PM
Waiting on my $GPUS Like 🫣 🙄MOVE YO AZZ ALREADY!$$$ jk $RDHL $OCG $SAFX
0 · Reply
SchumpeterSchlaumeier
SchumpeterSchlaumeier Jan. 6 at 7:32 PM
$RDHL squeeze блядь ! I'm with RDHL since 2019 and still believe in this dump🤜🤜🤜
0 · Reply
pln63
pln63 Jan. 6 at 6:48 PM
$RDHL fighting hard!
0 · Reply
DonZulu
DonZulu Jan. 6 at 3:14 PM
$RDHL flagging up
0 · Reply
pln63
pln63 Jan. 6 at 2:55 PM
$RDHL and another thing…Because it uses an established drug (ondansetron) in a new extended-release format, they are using the accelerated 505(b)(2) regulatory pathway, which significantly shortens the time to potential market entry😃
0 · Reply
pln63
pln63 Jan. 6 at 2:33 PM
$RDHL yesterday’s announcement was huge.Their GLP-1 Companion (RHB-102) gives access to a massive market for those needing nausea management. The accompanying nausea is no joke. Multi billion dollar industry potential. Nondilutive cash infuse with the recent $10.5 million legal battle win. I like it 
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 6 at 2:25 PM
$RDHL RSI: 63.83, MACD: -0.0158 Vol: 0.08, MA20: 1.17, MA50: 1.19 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
StockScanners
StockScanners Jan. 6 at 6:43 AM
$RDHL keep watch if this holds above 1.25
0 · Reply
Stockking24
Stockking24 Jan. 6 at 1:59 AM
$RDHL if this can get back over $2 and hold above that level then I’ll Start looking at but until then this remains just a buy the news sell The news rug of war will see.
0 · Reply
pln63
pln63 Jan. 5 at 8:59 PM
$RDHL this one is so flying under the radar
0 · Reply
Lalalalalalalala
Lalalalalalalala Jan. 5 at 6:00 PM
$RDHL wrong again buddy, huh?
0 · Reply
Stockwalker01
Stockwalker01 Jan. 5 at 5:50 PM
$RDHL Might still go, but I’m out for now.
0 · Reply
JohnTrack
JohnTrack Jan. 5 at 5:49 PM
$RDHL keeping this alive on the list!
0 · Reply
WestCoastBullz
WestCoastBullz Jan. 5 at 5:31 PM
Seeing bulls rotate into PAVM now. Starting its massive run - Early positioning is key 💎 Low float tickers have been exploding 300% lately. Just 700k shares outstanding, don't miss PAVM ! $RDHL $SOWG $BKKT $SLAI plays,.
0 · Reply
SelectiveTrader
SelectiveTrader Jan. 5 at 5:11 PM
Good afternoon, my afternoon day trade watch list at the moment part 1: $UAVS $VRME $JCSE $ALT $RDHL
0 · Reply
Stockwalker01
Stockwalker01 Jan. 5 at 4:57 PM
$RDHL
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Jan. 5 at 4:40 PM
$RDHL RedHill Biopharma shares are trading higher after the company announced development progress for RHB-102.
0 · Reply
DonZulu
DonZulu Jan. 5 at 4:04 PM
$RDHL new zone forming
0 · Reply
pln63
pln63 Jan. 5 at 3:28 PM
$RDHL I like the volume here!
1 · Reply